Member Info for Mnemosyne

I'd missed an announcement: http://www.investegate.co.uk/Article.aspx?id=201011080700417655V Good future revenues, plenty of cash and a plan in progress for plugging the hole in the pension scheme. No wonder we're looking perky today. Long may it last.

Hmm ... did you really just announce that you've just bought shares in this company on the back of market-sensitive inside info that hasn't yet been released?

A series of contract wins and reasonably decent results and the SP continues to languish regardless. Then an RNS stating Arbuthnot downrates us to Buy from Strong Buy, and the SP promptly pops up to the consolidation level again, for the first time since it happened. This share will drive me to drink!

Yes. I particularly liked: "We have begun to address the US market, which is the largest market for Optim and there has been considerable interest from both customers and potential distribution partners alike. We hope to update the market shortly on the appointment of a major distribution partner in the US." Also " ... the integration of Reactivlab into Avacta has proceeded as we now finalise new diagnostic test kits based on Reactivlab's intellectual property with a global commercial partner which plans to take these to market next year." Promising stuff.

This is a little more cheerful - goodness knows we need it. WPP sales leap signals return of the advertising spend http://www.thisismoney.co.uk/markets/article.html?in_article_id=517388&in_page_id=3&position=moretopstories

Yes, and good to have an update on a different project too, as well as the diagnostic equipment. Depression medication is an enormous market. Anything that can help tailor it to the individual and improve its effectiveness has got to have great commercial potential.

I got out of IMJ last December at 3.53p, at a 50% loss, having read everything I could find online about Mr. Morris and his projects, including ImJack when it was Amteus, and also Jeftel. It was one of my very first AIM buys, and a salutary lesson to me in researching properly before I part with cash. I've monitored IMJ with interest through the suspension and relaunch, and would not reinvest myself even at the current price (though if it did take off I would be delighted for those invested here!). I do wonder what Tanya Byron and Anthony Lilley think about their brief involvement with ImJack/Kwercus, and their hasty and low-profile severing of links shortly afterwards. I'm honestly not deramping, but I would urge people to research the history of this one very carefully indeed before making any investment decisions.

Hmm. 50-day SMA looks set to cross above the 200. I wonder whether we'll break 50 again, and keep going this time? That would be nice.

Interesting buys yesterday and today; £70k in just four ordinary transactions. The more (no pun intended) I look at EV, the more convinced I am that it's all about this Tim Moor guy and his Northumbria university contacts. Reading between the lines, the original diabetes screener he invented may well have come out of his college work (an MA project?) Avacta's take on the technology has been independently developed, so I wonder whether it's a case of Moor persuading Avacta that his invention can be added to theirs to get a viable product into the mainstream? If so, he must be very persuasive, or Avacta must be willing to risk a long shot for a possible steady income stream. Moor's obviously an interesting and talented bloke, but seems to have a ragbag of disconnected interests from Lake District gin to baby bottles, and he's been trying to get diabetes breath kits off the ground for ten years already. I like Avacta and I have faith it will come good, but I am not holding my breath over this one.

Emerging Metals Limited Notice of Annual General Meeting For immediate release: 28 September 2010 Emerging Metals Limited ("EML", "Emerging Metals" or "the Company") Notice of Annual General Meeting Emerging Metals Limited (AIM: EML), the mining company focused on minor and emerging metals, informs shareholders that the Annual General Meeting of shareholders will be held at The Sanderson Suite, The Claremont Hotel, 18-22 Loch Promenade, Douglas, Isle of Man, IM1 2LX at 10:00 a.m. on 20 October 2010. A copy of the Notice of Annual General Meeting together with the audited accounts of the Company for the financial period ended 31st March 2010 has been posted to shareholders and will shortly be available on the Company's website www.emergingmetals.com. -- Ends --

Nice little upward blip this morning, on relatively small volume. We're not due anything, I don't think, but I'm not complaining.

Tsumeb, forsooth! Can't tell my AFEs from my EMLs.

What brings you to that conclusion? Since all the figures are to YE March 2010, predating the Special Dividend and the disposal of the remaining investments in KAH and Extract, they have little relevance to the company's current position. As far as I can see, Dutwa has been written off as a dead duck at a cost of £5.3m, and investors are entirely dependent on the BOD's own investing expertise. Since we don't know what they are considering or doing, it's impossible to predict what this share will do next. The BOD did well with KAH, and I did nicely out of it thanks to them, but this share is a total punt and I freely accept that I could just as easily lose the lot next time round.

FAROE PETROLEUM PLC ("Faroe Petroleum", "Faroe", the "Company" or the "Group") Unaudited Interim Results for the six months ended 30 June 2010 Faroe Petroleum, the independent oil and gas group focused on oil and gas exploration in the Atlantic Margin, Norway and the North Sea, announces its unaudited Interim Results for the six months ended 30 June 2010. Highlights Operations * Significant gas and condensate discovery in the Fogelberg well in Norway (Faroe 15%) in April * Significant oil discovery in the Maria well in Norway (Faroe 30%) in July * Average oil and gas production of approximately 1,360 boepd * Pre-qualified as operator in Norway Financial and Corporate * Successful rights issue raising £65.2m (net of expenses) to fund forward drilling programme * Cash of £80.6m at 30 June 2010 (31 December 2009 adjusted: £33.1m). * Access to over £72.5m credit, comprising £50m for Norway exploration and £22.5m borrowing base facility * Turnover of £9.3m (1H 2009: £2.9m) * Loss before tax of £3.8m (1H 2009: £6.1m loss) * Board further strengthened with appointment of Ms Hanne Harlem as Non-Executive Director Outlook * Exciting drilling programme targeting 5 wells per year, with current 7 firm and 7 expected wells scheduled up to 2012, including 8 in Norway, 5 in the Atlantic Margin and 1 in UK North Sea * Anne Marie and Lagavulin wells to be drilled in the Atlantic Margin in the second half of this year * Well positioned to achieve significant programme expansion and growth in portfolio value http://www.investegate.co.uk/article.aspx?id=20100921070000H5531&fe=1

I tend to agree, and I have a little holding of just under 500k of these tucked away for the long term. This is interesting, though: http://www.thestar.co.uk/features/Invention-39a-first39-for-.4796815.jp. Certainly confirms that EV have been in the diabetes breath test business for a long time, but I am wondering why they seem to have made relatively little progress follwing their patent. EV's plan was to have this available to GPs by October 2010. I suspect the EV Analyser wasn't all it was cracked up to be (the article implies it only detected acetone) and Aviva's laser-based kit is better (it appears to detect more than one gas in the breath). Anyway, a while before we see a return, but EV seem committed to commercialising this technology and 10% of a potentially large net sale would be a very nice income stream for Avacta.

Avacta Group plc ("Avacta" or "the Company"), the biophysics company which provides innovative high value technologies and services to the biopharmaceutical and diagnostics markets, announces that it has entered into an agreement with EV (Medical Screening) Limited ("EV") for the exclusive worldwide rights to Avacta's laser based breath diagnostics technology. Avacta acquired the above technology in 2007 and has developed it into a viable method of breath diagnostics and industrial gas sensing with several prototypes having been completed. EV is focused on becoming a world leading breath diagnostic company and has identified Avacta's technology as being capable of providing an accurate and sensitive method of detecting certain gases in human breath. EV is focused initially on non-invasive methods of screening the population for, and monitoring the treatment of, diabetes and expects to bring products to market within two years based on Avacta's and other technologies. This represents a multi-billion dollar worldwide market and Avacta will receive a royalty of 10% of net sales on products developed using its technology. Alastair Smith, Chief Executive, Avacta Group plc commented: "It is well recognized that there is a huge potential market for a non-invasive screening/monitoring tool for diabetes. The Avacta gas analysis technology has the potential to provide a rapid, non-invasive and accurate method of screening the population for diabetes and this is an area that Avacta had identified as ideal for its technology for some time. Our limited resources have not allowed Avacta to focus on human diagnostic applications to date but this license agreement with EV will accelerate the commercialisation of the technology in a valuable application area." 20 September 2010 http://www.investegate.co.uk/article.aspx?id=20100920070000P11D6&fe=1

Look back 6 months in the chat or the RNS history. The company disposed of assets and distributed a special dividend of 7.13p per share. The reduced assets were reflected in a lower share price.

Well spotted! Good news. Here's the link: http://www.avacta.com/avacta_group/group_news/appointment_of_distributor_and_further_optim_sale

ummm... no and yes, actually. No, I'm not in TSW any more, having sold my remaining holding in two tranches at a ridiculously healthy profit over the past couple of weeks, with a gut feeling that it had given me all it could over 12 months. And yes, I did go into IQE at 25.19; I looked at it purely as a result of your posts here a fortnight ago. That holding is 25% up today, so cheers :)

Yes, looks like one of the big boys took a stake. I don't think we're due any major news, although the earlobe keloid removal trial and the one-dose paediatric formula are both set to report in H2 2010. Good to see some serious interest here.